Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
July 2017
Eficacia, Seguridad, Farmacocinética y Farmacodinamia de Filgotinib, un inhibidor selectivo de la quinasa Janus 1, después de tratamiento a curto-plazo de Artritis Reumatoide: Resultados de dos Ensayos Aleatorizados, fase IIA
Arthritis Rheumatol. 2017 Oct;69(10):1949-1959. doi: 10.1002/art.40186
In two 4-week exploratory Phase 2a trials in MTX-inadequate responder (IR) patients with RA, the highly selective JAK1 inhibitor filgotinib met the primary endpoint of ACR20 at Week 4, showing greater response than placebo.Study 1, a proof-of-concept study, included 127 patients randomised to placebo, filgotinib 100 mg BID or filgotinib 200 mg QD. Study 2, was a dose-ranging study and included 91 patients randomised to placebo, filgotinib 30 mg QD, filgotinib 75 mg QD, filgotinib 150 mg QD or fi...